Risks Of Probiotics In Newborns Doctors Are Debating
- 01. What can go wrong with probiotics in newborns?
- 02. Which newborn populations are at highest risk?
- 03. Common side effects and tolerability
- 04. Regulatory and product-quality concerns
- 05. When might probiotics be considered in newborns?
- 06. Practical guidance for parents and clinicians
- 07. Illustrative risk-benefit overview
- 08. Key questions and concise answers
Probiotics in newborns are generally considered low-risk for healthy, term infants, but emerging evidence highlights several serious potential harms-especially in preterm babies, critically ill infants, and those with immune-compromising conditions. These risks range from mild gastrointestinal side effects to invasive bloodstream infections, including lethal probiotic-associated sepsis, which has prompted regulatory warnings from the U.S. Food and Drug Administration and the American Academy of Pediatrics.
What can go wrong with probiotics in newborns?
Probiotic-induced infections are the most alarming risk, particularly in very low birth weight infants and those in neonatal intensive care units (NICUs). A 10-year analysis of multi-strain probiotic formulations in preterm infants found that bloodstream infections stemming directly from probiotic organisms occurred in about 0.6% of exposed babies (12 out of 2,109), with no deaths directly attributable, but several cases still required intensive treatment. These infections typically involve Bifidobacterium or Lactobacillus species contained in the product, and they can mimic typical neonatal sepsis signs such as fever, poor feeding, and respiratory deterioration.
For preterm infants with immature gut barriers and underdeveloped immune defenses, live microorganisms in supplements may translocate from the gastrointestinal tract into the bloodstream, especially when the gut is injured or when the infant is receiving central venous lines. In 2023, the FDA issued a formal warning letter to clinicians after a premature infant given a commercial probiotic product developed fatal Bifidobacterium-longum-associated sepsis, reinforcing the agency's stance that no probiotic product is FDA-approved for infants. As a result, many NICUs now restrict or avoid routine probiotic administration in the most vulnerable infants.
Outside the NICU, healthy term newborns nearly always tolerate probiotics well, but rare systemic events have still been reported. A systematic safety review of 57 clinical trials in infants under two years-covering more than 10,000 infants-found that most adverse events were considered unrelated to the probiotic product, and no major safety signals emerged for the evaluated strains when used in selected populations. However, the same review noted that the data were sparse for the first weeks of life and that trials often excluded the sickest infants.
Which newborn populations are at highest risk?
- Preterm infants, especially those weighing less than 1,000 g, face higher chances of probiotic-associated bacteremia due to fragile gut barriers and prolonged NICU stays.
- Critically ill newborns with central lines, ventilators, or major surgery may be more susceptible to sepsis from live microbial products.
- Babies with congenital immune disorders, short-gut syndrome, or other severe chronic conditions can experience more severe outcomes from probiotic-related infections.
- Infants with central nervous system shunts or other implanted devices may be at increased risk if bacteraemia spreads to hardware sites.
In high-risk groups, the risk-benefit calculus for probiotics shifts: while some strains may reduce antibiotic-associated diarrhea or certain forms of gastrointestinal inflammation, the absolute benefit is modest and can be outweighed by even rare sepsis events. In response, the American Academy of Pediatrics advises against routine probiotic use in U.S. NICUs, citing regulatory gaps, product-quality concerns, and these rare but serious infections.
Common side effects and tolerability
Even in healthy newborns, probiotics can trigger mild, transient side effects. The most frequently reported include gas, bloating, and increased spitting up or fussiness, particularly in the first few days of use. These symptoms are usually self-limiting and often resolve when the dose is reduced or the supplement is discontinued.
Randomized trials of probiotic-supplemented formulas in healthy term infants have generally found equivalent growth and similar adverse-event rates compared with control formulas over six months, suggesting good overall clinical tolerance. For example, a 2025 multicenter trial evaluating Limosilactobacillus reuteri and Bifidobacterium lactis in formula-fed infants reported no increased risk of vomiting, diarrhea, or urinary D-lactate levels, and weight gain was comparable to unsupplemented formula. Nevertheless, because strain-specific effects differ, these findings cannot be generalized to all probiotic products.
Regulatory and product-quality concerns
The regulatory status of probiotics for infants is a major source of uncertainty. In the United States, all probiotics marketed for infants are sold as dietary supplements, not FDA-approved drugs, which means they are not subject to the same rigorous pre-market testing for safety and efficacy. This lack of standardization raises concerns about strain accuracy, contamination, and batch-to-batch variability, especially in high-risk infants.
In 2023, the FDA explicitly warned clinicians that preterm infants given probiotics are at risk of invasive, potentially fatal infections caused by the microorganisms contained in probiotics. That same year, the American Academy of Pediatrics released a clinical report stating that, given the absence of pharmaceutical-grade products, conflicting data on safety and efficacy, and documented harms, routine universal probiotic administration to preterm infants-particularly those weighing under 1,000 g-is not supported. Many experts now recommend reserving probiotics for research-grade formulations used under strict institutional protocols rather than consumer-grade supplements at home.
When might probiotics be considered in newborns?
Under careful medical supervision, probiotics may be justified in specific clinical scenarios. For example, some randomized trials in preterm infants have shown reductions in necrotizing enterocolitis (NEC) and overall mortality when using rigorously controlled multi-strain preparations, though these data are largely observational or confined to high-income NICUs. A 2025 Pediatrics cohort study of 33 Canadian NICUs reported lower mortality in centers using probiotics, but also documented a small number of probiotic-associated sepsis cases, underscoring the need for caution.
For healthy term newborns, the evidence does not support routine supplementation. Benefits such as modest reductions in antibiotic-associated diarrhea or limited improvement in infant colic are strain-specific and often small in magnitude. Because the microbiome develops naturally through breastfeeding, vaginal birth, and early environmental exposures, many professional societies-including the European Academy of Allergy and Clinical Immunology (EAACI)-do not recommend routine probiotics for allergy prevention in infancy.
Practical guidance for parents and clinicians
- Avoid giving over-the-counter probiotics to preterm, very low birth weight, or critically ill newborns without explicit guidance from a neonatologist.
- For healthy term newborns, do not use probiotics routinely; reserve them for specific indications such as short-term management of antibiotic-associated diarrhea, and only under medical supervision.
- Scrutinize product labels to ensure the strain name, CFU count at expiry, and storage instructions are clearly stated, and, when possible, choose products with third-party verification such as USP Verified.
- Discontinue probiotics immediately if the infant develops fever, lethargy, poor feeding, or signs of sepsis, and seek urgent medical care.
- Discuss any plan to use probiotics in the neonatal period with the pediatrician or neonatal team, especially if the baby has a history of immune or gastrointestinal disorders.
Even when benefits are plausible, clinicians must weigh the individual risk profile of the newborn. For example, a preterm infant with multiple comorbidities may face a higher baseline risk of NEC but also a higher risk of invasive infection if given probiotics, making the decision highly context-dependent. In such cases, institutional guidelines, local surveillance data, and consultation with infectious-diseases and microbiome specialists are essential.
Illustrative risk-benefit overview
| Population | Key benefits (approximate) | Key risks (approximate) | Professional stance |
|---|---|---|---|
| Healthy term newborn | Small reduction in antibiotic-associated diarrhea; marginal improvement in some functional gastrointestinal symptoms | Rare mild GI side effects; extremely rare serious infections | Not recommended for routine use; reserve for specific indications with medical guidance |
| Preterm infant (NICU) | Up to ~20-30% relative reduction in NEC incidence in some trials; modest mortality reduction in observational cohorts | Approximately 0.5-1% risk of probiotic-associated bacteremia in large cohorts; lethal cases reported | Do not use routinely; restrict to rigorously controlled protocols in research or high-quality NICUs |
| Critically ill or immunocompromised newborn | Limited high-quality evidence of benefit; effects may be negligible | Higher risk of severe probiotic-associated sepsis and multi-organ involvement | Generally contraindicated; probiotics should be avoided without strong justification and expert oversight |
Key questions and concise answers
Key concerns and solutions for Risks Of Probiotics In Newborns Doctors Are Debating
Are probiotics safe for all newborns?
Probiotics are generally safe for healthy term newborns when used appropriately, but they are not universally safe for all infants. Preterm, critically ill, and immunocompromised newborns face higher risks of invasive infections, and many professional societies advise against routine administration in these groups.
Can probiotics cause infections in newborns?
Yes, probiotics can cause probiotic-associated bloodstream infections in newborns, especially in very low birth weight infants and those in the NICU. These infections are rare on a population level but can be life-threatening and have led to at least one documented infant death linked to a hospital-administered probiotic product.
What are the most common side effects of probiotics in babies?
The most common side effects in infants include gas, bloating, and mild increases in fussiness or spitting up, particularly in the first few days of use. These symptoms are usually temporary and resolve with dose adjustment or discontinuation; serious adverse events remain uncommon in healthy term babies.
Should I give probiotics to a preterm baby?
Most experts and organizations, including the American Academy of Pediatrics, recommend against routine probiotic use in preterm infants without strict medical oversight. If a NICU team considers probiotics, they typically use tightly controlled, research-grade formulations rather than consumer supplements, and monitor closely for signs of invasive infection.
Are there any probiotic products approved for newborns?
No probiotic product is currently FDA-approved as a drug or biological product specifically for use in infants. All such products are marketed as dietary supplements, which face looser regulatory requirements than pharmaceuticals, contributing to concerns about strain authenticity and contamination.
When should parents stop giving probiotics to a newborn?
Parents should stop giving probiotics to a newborn immediately if the infant develops fever, lethargy, poor feeding, rapid breathing, or any signs suggestive of sepsis or severe illness. They should contact a pediatrician or seek emergency care without delay, as probiotic-associated bacteremia can progress rapidly in vulnerable infants.
Can probiotics help with colic or gas in newborns?
Some studies suggest that specific strains, such as Lactobacillus reuteri, may modestly reduce crying time in formula-fed infants with colic, but the overall evidence is mixed and effects are often small. For many healthy term newborns, routine probiotic use for colic is not strongly supported, and benign interventions such as feeding adjustments and gentle settling techniques are often preferred first-line strategies.
What should parents look for when choosing a probiotic product?
Parents should look for clear labeling of the exact strain name, CFU count at expiry, and recommended storage conditions, and, when possible, choose products with third-party verification such as USP Verified. Avoid products that make disease-prevention or treatment claims for infants, because no probiotic is FDA-approved for disease prevention in this age group.